Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2405925 | 0.72 | CA12 (0.35) | ALDH1A1CYP1A2CYP2C19CA12CA1 | |
| SCHEMBL21598399 | 0.71 | — | — | |
| SCHEMBL17372681 | 0.71 | — | — | |
| SCHEMBL17372666 | 0.71 | — | — | |
| SCHEMBL16693757 | 0.69 | GRM5 (0.42) | PGK1ALDH1A1CYP1A2CYP3A4HSD17B10 | |
| SCHEMBL2067811 | 0.68 | PGK1 (0.37) | PGK1ALDH1A1CYP1A2CYP3A4HSD17B10 | |
| SCHEMBL1855211 | 0.68 | KDM4E (0.34) | ALDH1A1KDM4EMAPK1SMN1; SMN2CA12 | |
| SCHEMBL17372615 | 0.67 | USP8 (0.39) | ALDH1A1TDP1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL8641879 | 0.67 | ALDH1A1 (0.37) | ALDH1A1CYP1A2CYP3A4HSD17B10TDP1 | |
| SCHEMBL4475478 | 0.65 | GRM5 (0.54) | ALDH1A1CYP1A2CYP3A4HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049490-A1 | N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL]-L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS | Astra Zeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-20090062267-A1 | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| WO-2008125811-A1 | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255183-A1 | N-[HETEROARYLCARBONYL]-3-THIENYL-L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| WO-2008093065-A1 | L-ALANINE DERIVATIVES AS α5βL ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008093064-A1 | L-ALANINE DERIVATIVES AS α5 BETA 1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | WO | disclosed |
| US-20080182842-A1 | L-alanine derivatives as a5beta1 antagonists | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| WO-2007141473-A1 | N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255183-A1 | N-[HETEROARYLCARBONYL]-3-THIENYL-L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ITGA2B, ITGB1, ITGB5 | PGK1 4433/4885ALDH1A1 559/4885CYP1A2 4340/4885 |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ITGB5, ITGB1, ITGA2B | PGK1 2301/4885ALDH1A1 1037/4885CYP1A2 3894/4885 |
| US-20090062267-A1 | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ITGA2B, ITGB1, ITGAL | PGK1 4021/4885ALDH1A1 437/4885CYP1A2 4334/4885 |
| US-20080182842-A1 | L-alanine derivatives as a5beta1 antagonists | ITGB1, ITGA2B, ITGB5 | PGK1 4029/4885ALDH1A1 345/4885CYP1A2 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.